Sofinnova Ventures' New $440M Eighth Fund Exceeds Expectations And Makes Adjustments
This article was originally published in The Pink Sheet Daily
The firm wins higher commitments from limited partners, turning its health-care focus to late stage companies and forgoing high-tech investments.
You may also be interested in...
Newly launched dermatology start-up Aclaris brings the band back together, as Vicept’s core management and VCs begin a new endeavor in a sometimes-neglected sector.
Who has recently topped up, and who’s running on empty? START-UP’s annual gas-tank review of venture fundraising shows how consolidation has hit the sector hard in the past twelve months, as limited partners concentrate their money in specialized funds that have demonstrated an ability to deliver returns.
There are good-value opportunities in Europe for VCs with money to invest, but those seeking new funds face an unprecedentedly tough challenge that’s compounded by euro uncertainty.